Molecular Profiling of an Exceptional Responder and a Non-Responder to Platinum Based Chemotherapy in Two Patients with Advanced Urothelial Cancer

Tingrui Wang1, Zonghui Ding2, Jue Wang3*

1Department of Internal Medicine, St. Joseph’s Hospital and Medical Center, Phoenix, Arizona
2Department of Biochemistry and Molecular Biology, Mayo Clinic Arizona, Scottsdale, Arizona
3The University of Arizona Cancer Center at St. Joseph’s Hospital and Medical Center, Phoenix, Arizona

Abstract

Background: Understanding the molecular mechanisms of sensitivity to anticancer therapies may improve patient selection, response to therapy, and clinical trial designs. One approach to increase this understanding involves detailed studies of exceptional responders who achieved exquisite sensitivity or durable responses to therapy, and non-responders who have intrinsic or acquired drug resistance to therapy.

Case presentation: Case 1: A 72-year-old man developed multiple lung metastases three years after initial diagnosis of low-grade urothelial carcinoma followed with left nephroureterectomy and multiple courses of intra-vesical BCG therapy. He was enrolled into a randomized, phase III study of gemcitabine/cisplatin plus/minus bevacizumab therapy. He had a near complete response after two cycles of chemotherapy. The samples from his primary tumor and metastatic lesions were examined with a battery of immunohistochemical and molecular assays.

Case 2: A 41-year-old female with history of pT3bpN2, high-grade transitional cell carcinoma of the bladder, status post radical cystectomy received four cycles of adjuvant gemcitabine/cisplatin. Three months afterwards, she was found with large pelvic metastases. The samples from her pelvic mass were examined with immunohistochemical and molecular assays.

Conclusion: Case 1 patient has low expression of ERCC1 and RRM1 and mutations of BRCA1 and ATM. Case 2 patient has amplification of AKT1. The molecular profiling of two cases provides potential explanation for the exceptional response and non-response to gemcitabine/cisplatin respectively. Other actionable gene alterations provide rational basis for future targets. An in-depth analysis of tumor molecular profile will facilitate new drug development and provide new insights into urothelial carcinoma.

Keywords: Molecular profiling; Gemcitabine; Cisplatin; Urothelial cancer

Introduction

Urothelial cancer is the fourth most common cancer in men in the U.S.[1]. More than 76,960 Americans will be diagnosed with bladder cancer this year (58,950 men and 18,010 women), and more than 16,390 (11,820 men and 4,570 women) can expect to die of their disease[2]. Advances in the management of metastatic bladder cancer have been limited. Chemotherapy with platinum-based regimes remains the mainstay of first-line treatment and standard of care in metastatic urothelial carcinoma.

Antitumor effect of cisplatin chemotherapy is attributed to formation of platinum DNA adducts and other DNA helix-dis-
torting lesions which could be repaired by the nucleotide excision repair (NER) system\(^2,3\). Excision repair cross complementation group 1 enzyme (ERCC1) exerts an important role in NER pathway and removal of platinum DNA adducts induced by cisplatin\(^4\). In bladder cancer, several studies have shown that ERCC1 is a potential prognostic and predictive marker of the efficacy of platinum based chemotherapy\(^5-8\). High tumor expression of ERCC1 is correlated with shorter survival in those with platinum based chemotherapy\(^6\).

Ribonucleotide reductase subunit M1 (RRM1) is the regulatory subunit of ribonucleotide reductase (RR) which converts ribonucleotides to deoxynucleotides and participates in DNA synthesis and repair. Gemcitabine, a pyrimidine nucleoside antimetabolite, inhibits DNA synthesis by inhibiting RR. Several studies have suggested the RRM1 is associated with resistance to gemcitabine based chemotherapy\(^6\). Breast cancer 1 (BRCA1) plays a key role in DNA repair as well and low levels of BRCA1 can predict response to cisplatin. Decreased BRCA1 expression in bladder cancer resulted in greater cisplatin sensitivity\(^10\). Akt (protein kinase B) is a serine/threonine kinase which plays an important role in cellular survival. Akt is activated in response to growth factors and once activated Akt exerts anti-apoptotic effects and contributes to chemotherapeutic resistance. One study showed that Akt mediated BAD phosphorylation led to paclitaxel resistance in T24 human bladder cancer cells\(^11\). However, the case that Akt promotes resistance to gemcitabine/cisplatin has not been reported.

Understanding the molecular mechanisms of sensitivity to anticancer therapies and genetic basis of chemotherapy response may improve patient selection, rational treatment designs and response to therapy. One approach to increase this understanding involves detailed studies of exceptional responders and non-responders to gemcitabine/cisplatin based chemotherapy.

**Case Presentation**

**Case 1**

A 72-year-old man developed multiple lung metastases three years after initial diagnosis of low-grade papillary urothelial carcinoma followed with left nephroureterectomy and multiple courses of intravesical BCG therapy. One lung metastasis lesion was biopsied and pathology confirmed the diagnosis of metastatic urothelial cancer. The malignant cells were immuno-histochemically positive for CK7, p63, p40, S100, and CK5/6. Stains for Napsin A and TTF1 were all negative. The tumor expressed high level of TOPO1, TLE3, MGMT, EGFR, SPARC, PGP and TUBB3, and negative for ERCC1, PTEN, TS, TOP2A, and RRM1 (Figure 1). Molecular study of his nephrectomy sample with ASHION Analytics GEM Cancer PanelTM showed multiple genomic alterations including ATM (G204); CCND1 amplification; FGFR3 (S249C); PTEN deletion. A Cell-free Tumor DNA test showed multiple alterations including FGFR3 S249C; RET E595E; TP53 V173M; TP53 C176*; TP53 V143M; BRCA1 Q780*.

![Figure 1](image1.png)

He was enrolled into a randomized, phase III study of gemcitabine/cisplatin plus/minus bevacizumab therapy for patients with metastatic urothelial cancer. He had a near complete response after two cycles of chemotherapy on the clinical trial. Chest CT was obtained before the therapy started, which showed a mass 61.2 mm x 48.0 mm in right upper lung. The lung mass remarkably decreased after two cycles (Figure 2). The patient subsequently received additional therapies at the time of disease progression and survived for more than five years.

**Case 2**

A 41-year-old female presented with pT3bpN2 high-grade transitional cell carcinoma of the urinary bladder underwent radical cystectomy followed with four cycles of gemcitabine/cisplatin after surgery. Three months afterwards, she was found with large pelvic mass 9.50 cm in greatest diameter (Figure 3) and CT guided biopsy of pelvic mass confirmed metastatic high grade urothelial carcinoma. She subsequently developed liver metastasis and died one year after initial diagnosis. The tumor was immunohistochemically strong positive for GATA3 and p63. Molecular study of her pelvic mass with ASHION Analytics GEM Cancer PanelTM showed multiple genomic alterations including AKT1 amplification, DDR2(S755Y), RAF1 amplification.

![Figure 2](image2.png)
Molecular profiling of exceptional responder and non-responder

Discussion

Genomic profiling is a useful tool for understanding the molecular mechanism and etiology of urothelial carcinoma. Although molecular biomarkers are routinely used clinically to guide selected treatment for melanoma, lung cancer, colon cancer, the genomic molecular markers for bladder which predict the response to therapy are relatively lacking[12]. The study of extraordinary responses and non-response to chemotherapy has the potential to identify the novel molecular mechanisms of sensitivity and resistance to atitumor therapies. The low expression of ERCC1 and RRM1 and genomic alterations of BRCA1 and ATM in case 1 patient, likely explain the exceptional response to gemcitabine and cisplatin. Defective DNA repair renders tumor sensitive to cisplatin. The excision repair cross-complementation group 1 (ERCC1) is an important enzyme within the nucleotide excision repair (NER) pathway. Cisplatin induces DNA damage by formation of platinum-DNA adducts causing intra-strand and inter-strand DNA crosslinks. Cisplatin resistance is associated with removal of the adducts by NER system. Tumor cells deficient in ERCC1 impair the capacity of NER and may be more vulnerable to cisplatin[13]. Increased ERCC1 expression cause the cisplatin resistance in bladder cancer[9], cervical[14], ovarian[15], gastric[16], colon[17], non-small cell lung cancers(NSCLC)[18]. ERCC1 may represent a predictive marker for platinum based treatment in bladder cancer. Several studies have shown that high ERCC1 mRNA or protein expression is likely to cause the cisplatin resistance phenotype and correlated with poor prognosis treated with cisplatin based chemotherapy[3]. Sun et al. has shown that ERCC1 negative tumor benefit from adjuvant gemcitabine plus cisplatin chemotherapy as measured by overall survival and disease free survival[8].

Ribonucleotide reductase M1 (RRM1) is the regulatory subunit of ribonucleotide reductase holoenzyme (RR) that involves in the production of deoxyribonucleotides for de novo DNA synthesis and DNA repair. Gemcitabine is a deoxycytidine analogue, which inhibits RR activity. RRM1 is associated with resistance to gemcitabine-based chemotherapy and lower/nega-

tive RRM1 expression was associated with higher response to gemcitabine-containing treatment and better prognosis[19].

The breast cancer susceptibility gene 1 (BRCA1) is involved in the process of mitosis and also plays a predominant role in the repair of DNA damage. Loss of BRCA1 functions sensitize the activity of cisplatin in breast cancer animal model[20]. Low BRCA1 expression in bladder cancer resulted in greater cisplatin sensitivity[10].

Ataxia telangiectasia mutated (ATM) has a central role in DNA repair and it is mutated in 11% of urothelial carcinoma[21]. The response to DNA repair includes recognition of damaged DNA, repair protein, transcription regulation, and activation of apoptosis[22]. Defects in ATM increase sensitivity to chemotherapy in cell lines and animal models[23]. Higher numbers of ATM alterations correlate with response to cisplatin based chemotherapy[24]. ATM-deficient tumors may predict sensitivity to DNA damage agents such as platinum based therapy, as well as poly(ADP-ribose) polymerase (PARP) inhibitors[22]. Other actionable gene alterations (FGFR3, CCND1 and RET) provide rational basis for future targets.

Case 2 patient shows AKT1 amplification and presents with resistance to gemcitabine/cisplatin chemotherapy. Akt is cellular homologue of v-akt oncogene and has three isoforms, Akt1, Akt2, Akt3. Akt plays an important role in survival when cells are exposed to DNA damage and regulate the apoptotic machinery such as BAD or caspase-9[24]. Akt activity promotes breast cancer[25], glioma[26], NSCLC[27] progression and therapeutic resistance. Szanto et al. reported T24 human bladder cancer cells resistance to paclitaxel by Bad phosphorylation resulting from activation of PI-3K-Akt pathway and inhibiting this pathway could facilitate paclitaxel therapy[28]. Our case report first suggests that Akt also potentially induces gemcitabine/cisplatin resistance. This finding warrants further investigation in mechanism.

We realize the limitation of case study, however accumulations of these unique cases add to current understanding of precision medicine, which will be further tested in prospective trials. An in-depth analysis of tumor molecular expression in exceptional responders and non-responders may facilitate new drug development for advanced urothelial carcinoma.

Conclusion

Although next generation sequencing (NGS) of “N of 1” cases have identified mechanisms of exceptional response to investigational therapies in urothelial carcinoma, as far as we know, such approaches have not been applied to exceptional non-responders. Here, we describe NGS assessment of clinical samples from both exceptional responder and non-responder. The molecular profiling of tumors in the cases reported here provides potential explanation for the exceptional response and non-response to gemcitabine and cisplatin chemotherapy. Additional research is needed to validate our observation in prospective clinical trials.
Molecular profiling of exceptional responder and non-responder

Reference